Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Average Recommendation of “Hold” by Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been given an average recommendation of “Hold” by the nine research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $44.89.

Several research analysts have commented on the stock. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price on the stock in a research report on Wednesday, April 3rd. JMP Securities dropped their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Finally, Truist Financial dropped their price target on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st.

Integra LifeSciences Price Performance

IART opened at $28.41 on Friday. Integra LifeSciences has a twelve month low of $27.18 and a twelve month high of $56.41. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 0.88 and a beta of 1.12. The company has a fifty day simple moving average of $35.67 and a 200 day simple moving average of $38.83.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The business had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.94 earnings per share. Equities research analysts expect that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IART. Signaturefd LLC lifted its stake in shares of Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after buying an additional 415 shares in the last quarter. Hexagon Capital Partners LLC increased its stake in shares of Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 370 shares in the last quarter. Gladius Capital Management LP purchased a new position in Integra LifeSciences during the third quarter valued at $47,000. Valley National Advisers Inc. purchased a new position in Integra LifeSciences during the first quarter valued at $63,000. Finally, Covestor Ltd grew its stake in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 921 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.